Bone Sialoprotein BSP ELISA Assay
Bone Sialoprotein BSP ELISA Assay manufactured in Germany by Immundiagnostik
Size: 1×96 wells
Standard Range: 3.1-50 ng/ml
Incubation Time: 3 h, 1 h, 10-20 min
Sample Type: Serum, EDTA Plasma
Sample Size: 50 µL
For Research Use Only
Bone sialoprotein (BSP) is a phosphorylated glycoprotein that comprises 12 % of the total non-collagenous proteins in bone and is thought to be involved in bone mineralisation and remodelling. The polypeptide chain of BSP has a molecular weight of 35 kDa. Native BSP has an apparent molecular weight of 70–80 kDa due to complex post translational modifications involving glycosylation. BSP is synthesized mainly by skeletal-associated cell types, including fibroblasts, hypertrophic chondrocytes, osteoblasts, osteocytes, osteoclasts, as well as trophoblasts. BSP is overexpressed and underglycosylated in human primary breast and prostate cancers that metastasize to the bone, whereby BSP expression correlates with the development of microcalcifications. Underglycosylated BSP is also expressed by other tumours, such as lung cancer, thyroid cancer, multiple myeloma and neuroblastoma, that predominantly metastasise to bones.
This ELISA is designed for the quantitative determination of underglycosylated bone sialoprotein in serum and EDTA plasma. The test principle is based on interaction of the antigen in the samples or standards and with the antibody coated on the wells of the microtiter plate. A peroxidase-conjugated secondary antibody is used for detection and quantification, and tetramethylbenzidine (TMB) as a peroxidase substrate. The enzymatic reaction is terminated by an acidic stop solution. A dose response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated, using the values obtained from the standard. Bone sialoprotein, present in the patient samples, is determined directly from this curve.